A classification scheme based upon the presence or absence of both β-cell autoimmunity and β-cell function is the best predictor of the need for insulin treatment at 1 year in patients with ketosis-prone diabetes, according to Dr. Ashok Balasubramanyam, of Baylor College of Medicine, Houston, and his associates.